To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

Hozzl · 2025-03-12T08:07:40Z

Explore the details of House Bill 1262 To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

3/12/2025, 8:07 AM

Summary of Bill HR 1262

Bill 119 hr 1262, also known as the Pediatric Cancer Targeted Therapy Act, aims to make important changes to the Federal Food, Drug, and Cosmetic Act in order to improve the way pediatric cancer is researched and treated. The bill specifically focuses on molecularly targeted therapies, which are treatments that target specific molecules within cancer cells.

One of the key provisions of the bill is to encourage the development of more targeted therapies for pediatric cancer. This includes providing incentives for pharmaceutical companies to conduct research and clinical trials specifically focused on pediatric cancer treatments. By doing so, the bill aims to increase the availability of effective and less toxic treatments for children with cancer.

Additionally, the bill seeks to improve the coordination and communication between researchers, healthcare providers, and regulatory agencies when it comes to pediatric cancer investigations. This will help ensure that new treatments are developed and approved in a timely manner, while also prioritizing the safety and well-being of pediatric cancer patients. Overall, the Pediatric Cancer Targeted Therapy Act is an important piece of legislation that aims to improve the way pediatric cancer is treated in the United States. By focusing on molecularly targeted therapies and promoting collaboration among stakeholders, the bill has the potential to make a significant impact on the lives of children with cancer.

Current Status of Bill HR 1262

Bill HR 1262 is currently in the status of Bill Introduced since February 12, 2025. Bill HR 1262 was introduced during Congress 119 and was introduced to the House on February 12, 2025. Bill HR 1262's most recent activity was Referred to the House Committee on Energy and Commerce. as of February 12, 2025

Bipartisan Support of Bill HR 1262

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

196

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 1262

Primary Policy Focus

Alternate Title(s) of Bill HR 1262

To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

Start holding our government accountable!